menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Poster Pearl: Detecting Cancer with an MCED Test and Treating It Surgically Improves Outcomes

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    A poster presented at the 2023 American Society of Clinical Oncology Annual Meeting unveiled key findings from the longitudinal analysis on the DETECT-A study. One such finding was that patients who underwent surgery after their cancer was detected by a blood-based multi-cancer early detection (MCED) test had more positive outcomes compared to those who received treatment with chemotherapy, radiation therapy, or a kinase inhibitor. Learn more about these long-term clinical outcomes with Dr. Charles Turck and Mr. Adam Buchanan, Associate Professor and Chair of the Department of Genomic Health at Geisinger in Danville, Pennsylvania and co-author of the poster.

    This is a non-certified educational program produced and controlled by ReachMD and is intended for healthcare professionals only. This program discusses a technology under development. Any features discussed describe current development goals. It has not been cleared or approved by the U.S. FDA or any other national regulatory authority.

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    A poster presented at the 2023 American Society of Clinical Oncology Annual Meeting unveiled key findings from the longitudinal analysis on the DETECT-A study. One such finding was that patients who underwent surgery after their cancer was detected by a blood-based multi-cancer early detection (MCED) test had more positive outcomes compared to those who received treatment with chemotherapy, radiation therapy, or a kinase inhibitor. Learn more about these long-term clinical outcomes with Dr. Charles Turck and Mr. Adam Buchanan, Associate Professor and Chair of the Department of Genomic Health at Geisinger in Danville, Pennsylvania and co-author of the poster.

    This is a non-certified educational program produced and controlled by ReachMD and is intended for healthcare professionals only. This program discusses a technology under development. Any features discussed describe current development goals. It has not been cleared or approved by the U.S. FDA or any other national regulatory authority.

Facebook Comments

Schedule12 Apr 2024